Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q4 2018 · 10-K
Revenue$6.12M$6.12M+66.9% vs Q4 2017 Net Income-$25.05M-$25.05MN/M vs Q4 2017 EPS Diluted-$0.52-$0.52no prior Q4 2017 on file Operating Income-$26,253,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$88,000N/M Margins · derivedOperating margin-429.0%+564.7 pt vs Q4 2017
Net margin-409.4%+577.4 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 1, 2019 · 60 d after period end